1. DOP41 Achievement of corticosteroid-free clinical endpoints in subjects with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 trial. (30th January 2023) Authors: Sands, B E; Rubin, D T; Panés, J; Gecse, K B; Leung, Y; Goetsch, M; Wang, W; Shan, K; Woolcott, J; Smith, C C; Wosik, K; Schreiber, S W Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i106 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DOP42 Efficacy of etrasimod on symptomatic relief in patients with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials. (30th January 2023) Authors: Chaparro, M; Armuzzi, A; Irving, P M; Allez, M; Dubinsky, M C; Sands, B E; Goetsch, M; Wang, W; Shan, K; Woolcott, J; Bartolome, L; Wosik, K; Panaccione, R Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FRI0201 Etanercept retention patterns and factors associated with treatment discontinuation: a retrospective cohort study using canadian claims-level data. (15th June 2017) Authors: Khraishi, M; Zhang, Y; Ivanovic, J; Millson, B; Brabant, M-J; Charland, K; Singh, E; Woolcott, J; Jones, H Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 558 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P490 Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trials. (30th January 2023) Authors: Vermeire, S; Peyrin-Biroulet, L; Panés, J; Regueiro, M; Kotze, P G; Charabaty, A; Goetsch, M; Shan, K; Wu, J; McDonnell, A; Woolcott, J; Danese, S Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i619 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P574 Characterization of plasma inflammatory protein abundance in patients with ulcerative colitis treated with etrasimod: an exploratory analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials. (30th January 2023) Authors: Siegmund, B; Ryan, R; Abreu, M T; Vermeire, S; Dotan, I; Goetsch, M; Crosby, C; Woolcott, J; Komori, H K; Danese, S Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i700 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P575 Effect of etrasimod on immune cell subsets in colonic tissue of patients with ulcerative colitis: immunophenotyping analysis of colon biopsy samples from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials. (30th January 2023) Authors: Siegmund, B; Komori, H K; Abreu, M T; Vermeire, S; Dotan, I; Goetsch, M; Crosby, C; Ryan, R; Woolcott, J; Danese, S Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i701 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P699 The concordance of Short Form-36 Health Survey scores with Mayo scores in the tofacitinib ulcerative colitis clinical programme. (15th January 2020) Authors: Dubinsky, M C; Bushmakin, A G; Cappelleri, J C; Woolcott, J; Sharma, P; Maller, E; Salese, L; Armuzzi, A Journal: Journal of Crohn's and colitis Issue: Volume 14(2020)Supplement 1 Page Start: S566 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. SAT0165 Real-world utilization of concomitant medications in patients initiating etanercept: a retrospective cohort study of canadian claims-level data. (15th June 2017) Authors: Khraishi, M; Zhang, Y; Ivanovic, J; Millson, B; Brabant, M-J; Singh, E; Woolcott, J; Jones, H Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 832 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. THU0628 Patterns of etanercept dose adjustments in a real–world setting: a canadian retrospective cohort study. (15th June 2017) Authors: Khraishi, M; Zhang, Y; Ivanovic, J; Millson, B; Singh, E; Woolcott, J; Jones, H Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 443 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗